http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101086026-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-042 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2541-101 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-115 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2008-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2011-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101086026-B1 |
| titleOfInvention | DNA aptamer specifically binding to bispartin and its preparation method |
| abstract | The present invention relates to a DNA aptamer that specifically binds to bispartin, and more particularly, to a DNA aptamer that specifically binds to visfatin selected from a random DNA library and a method of preparing the same. . According to the present invention, a DNA aptamer showing a high affinity for bispartin, a biomarker of type 2 diabetes, from a random DNA pool was selected using the FluMag-SELEX process, a modified method of the SELEX process. The sequence, properties, and binding capacity of the selected DNA aptamers were analyzed. Therefore, the type 2 diabetes can be diagnosed more effectively by using the DNA aptamer of the present invention.n n n n Bispartin, DNA Aptamer, Type 2 Diabetes, Biomarker, Affinity, SELEX |
| priorityDate | 2008-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 44.